Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Senesco Technologies has begun the Phase 1b/2a clinical study of SNS01-T drug to assess the safety and tolerability of the drug when administered by intravenous infusion to relapsed or refractory multiple myeloma patients.
Subscribe to our email newsletter
The open-label, multiple-dose, dose-escalation study will also assess the impact of SNS01-T on time to relapse or progression and tumor response using multiple metrics.
Senesco president and CEO Leslie J. Browne said they are excited that the SNS01-T study is underway and intend to provide material updates as it progresses.
"Although the trial is primarily designed to confirm pre-clinical safety and tolerability in patients, we are keenly interested in getting a look at the battery of tumor response markers including M-protein and C-reactive protein that could provide evidence of a response," Browne added.
Senesco is also planning to open a second medical facility to improve the patient recruitment rate.